Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech’s obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
CREATE’s in vivo CAR-T achieves full B cell depletion and repeat dosing in primates
CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.